Scarica l'app Stockscreener
1,073.29
0.36%
-3.90
Pre-mercato:
1062.98
-10.31
-0.96%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché LLY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$1,077.19
Aprire:
$1081.75
Volume 24 ore:
1.90M
Relative Volume:
0.56
Capitalizzazione di mercato:
$960.61B
Reddito:
$59.42B
Utile/perdita netta:
$18.41B
Rapporto P/E:
53.08
EPS:
20.2197
Flusso di cassa netto:
$6.44B
1 W Prestazione:
-3.14%
1M Prestazione:
+4.46%
6M Prestazione:
+34.27%
1 anno Prestazione:
+44.08%
Intervallo 1D:
$1,061.12
$1,084.00
Intervallo di 1 settimana:
$1,058.00
$1,133.95
Portata 52W:
$623.78
$1,133.95
Lilly Eli Co Stock (LLY) Company Profile
Nome
Lilly Eli Co
Settore
Industria
Telefono
(317) 276-2000
Indirizzo
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Confronta LLY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,073.29 | 964.11B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
218.55 | 514.75B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
221.89 | 390.15B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
146.16 | 271.72B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
111.01 | 268.70B | 63.90B | 19.05B | 13.05B | 7.5596 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Ripresa | UBS | Buy |
| 2025-12-16 | Aggiornamento | Daiwa Securities | Neutral → Buy |
| 2025-12-15 | Reiterato | BofA Securities | Buy |
| 2025-12-15 | Reiterato | Goldman | Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-11-10 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | Reiterato | BMO Capital Markets | Outperform |
| 2025-10-14 | Aggiornamento | Erste Group | Hold → Buy |
| 2025-09-17 | Downgrade | Berenberg | Buy → Hold |
| 2025-08-27 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2025-08-18 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | Downgrade | Erste Group | Buy → Hold |
| 2025-04-28 | Downgrade | HSBC Securities | Buy → Reduce |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-09-13 | Ripresa | Citigroup | Buy |
| 2024-08-12 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-02-21 | Downgrade | DZ Bank | Buy → Hold |
| 2024-02-16 | Reiterato | Morgan Stanley | Overweight |
| 2023-12-21 | Downgrade | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-10-20 | Ripresa | UBS | Buy |
| 2023-08-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-26 | Reiterato | Citigroup | Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-05-24 | Reiterato | BofA Securities | Buy |
| 2023-05-24 | Reiterato | UBS | Buy |
| 2023-03-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-15 | Downgrade | Societe Generale | Hold → Sell |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-09-22 | Aggiornamento | UBS | Neutral → Buy |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2022-03-10 | Iniziato | Daiwa Securities | Outperform |
| 2022-01-21 | Aggiornamento | DZ Bank | Hold → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-16 | Reiterato | BMO Capital Markets | Outperform |
| 2021-12-16 | Reiterato | BofA Securities | Buy |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-10-11 | Aggiornamento | Berenberg | Hold → Buy |
| 2021-09-29 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-08-05 | Aggiornamento | DZ Bank | Hold → Buy |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-06-24 | Reiterato | Cantor Fitzgerald | Overweight |
| 2021-01-19 | Aggiornamento | Mizuho | Neutral → Buy |
| 2020-12-10 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-09-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-04-21 | Downgrade | UBS | Buy → Neutral |
| 2020-04-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2019-12-18 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-05-28 | Iniziato | Goldman | Buy |
| 2019-04-24 | Aggiornamento | Edward Jones | Hold → Buy |
| 2019-04-11 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-03-12 | Iniziato | JP Morgan | Overweight |
| 2019-01-23 | Iniziato | UBS | Buy |
| 2018-11-26 | Downgrade | Citigroup | Buy → Neutral |
| 2018-10-31 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | Iniziato | Guggenheim | Buy |
| 2018-10-01 | Reiterato | SunTrust | Buy |
| 2018-09-26 | Ripresa | JP Morgan | Overweight |
Mostra tutto
Lilly Eli Co Borsa (LLY) Ultime notizie
Digbi Health Publishes Peer-Reviewed Data Demonstrating Significant Cost Savings for Employers Via Its Precision Biology Telehealth Platform to Manage GLP-1, Metabolic, and GI Costs - GlobeNewswire Inc.
Arcadia Investment Management Corp MI Purchases 1,995 Shares of Eli Lilly and Company $LLY - MarketBeat
Ashton Thomas Securities LLC Takes Position in Eli Lilly and Company $LLY - MarketBeat
Compounding Pharmacy Accuses Eli Lilly, Novo Nordisk of Blocking GLP-1 Competition - USA Herald
Eli Lilly’s Strategic Moves: FDA Timeline, AI Partnership, and Legal Hurdles - AD HOC NEWS
Eli Lilly, Novo Hit With Antitrust Suit From Drug Compounder (1) - Bloomberg Law News
Eli Lilly (LLY) and Novo Nordisk Face Legal Battle Over GLP-1 Dr - GuruFocus
Compounding pharmacy sues Lilly, Novo over GLP-1 drug competition - Seeking Alpha
Eli Lilly’s Next Strategic Move: An Oral Contender for the Weight-Loss Market - AD HOC NEWS
Strive Compounding Pharmacy Files Landmark Antitrust Lawsuit Against Eli Lilly and Novo Nordisk - PR Newswire
Behind the Scenes of Eli Lilly and Co's Latest Options TrendsEli Lilly and Co (NYSE:LLY) - Benzinga
NVIDIA and Eli Lilly Launch $1B AI Co-Innovation Lab to Reinvent Drug Discovery - Oncodaily
How Eli Lilly’s US$1 Billion NVIDIA AI Lab Could Reshape Growth, Margins and Pipeline (LLY) - simplywall.st
LLY Shows Positive Momentum Amid Obesity Drug Industry Developme - GuruFocus
Nvidia–Eli Lilly Tie-Up Shows Why AI Drug Discovery Is The Next ETF Battleground - Benzinga
NVIDIA and Eli Lilly Launch $1bn AI Drug Discovery Lab - AI Magazine
Lilly and NVIDIA unveil $1B co-innovation lab in South San Francisco - drugdiscoverytrends.com
JP Morgan 2026: Eli Lilly’s Continuing GLP-1 Success - PharmExec.com
BMO Capital Markets Pounds the Table on Eli Lilly Stock (LLY) - TipRanks
Nvidia and Eli Lilly bet $1 billion on AI-powered drug discovery - Longevity.Technology
Nvidia, Eli Lilly to Invest USD 1 Billion in AI Co-Innovation Lab for Drug Discovery - TelecomTalk
BMO Capital reiterates Outperform rating on Eli Lilly stock at $1,200 - Investing.com
Is It Time to Dump Your Shares of Eli Lilly? - Finviz
Eli Lilly and Company $LLY is Wealth Advisory Solutions LLC's 4th Largest Position - MarketBeat
Biogen CEO says at-home Alzheimer’s drug will give edge over Lilly - Investing.com
Biogen CEO Sees Edge Over Lilly With At-Home Alzheimer’s Drug - Bloomberg.com
Jim Cramer Calls Nvidia, Eli Lilly Partnership 'Monumental Effort' To 'Speed Up' Critical Drug Creation - Benzinga
NVIDIA, Lilly Launch AI Lab to Transform Drug Discovery Innovations - filmogaz.com
Eli Lilly Stock Rallies as Ventyx Deal Calms Wegovy Concerns - MarketBeat
French Government Shoots Down Rumors Eli Lilly (LLY) Is Planning to Acquire Biotech Firm Abivax - TipRanks
Eli Lilly CFO: Weight-loss pill could have 20% global penetration - Yahoo Finance UK
Illumina Announces Alliance Framework with AstraZeneca, Merck, and Eli Lilly and Company - marketscreener.com
Patients file lawsuits in Marion Co. alleging drug companies "downplayed" GLP-1 side effects - WRTV
Eli Lilly stock (LLY) edges up as FDA clears GLP-1 label cloud; $150 pill launch looms - TechStock²
JPM: Nvidia Launches AI Collaborations with Eli Lilly, Thermo Fisher - Genetic Engineering and Biotechnology News
Eli Lilly vs Novo Nordisk: Which Company Will Dominate the Weight Loss Drug Market in 2026? - Finviz
Nvidia, Eli Lilly Launch $1 Billion AI Lab To Build Meds - Benzinga
The Zacks Analyst Blog Highlights Microsoft, Eli Lilly, Lam Research and Ampco-Pittsburgh - Yahoo Finance Singapore
Nvidia Drives 70% Drug‑Discovery Cost Crash; Lilly Bets $1BEli Lilly and Co (NYSE:LLY), NVIDIA (NASDAQ:NVDA) - Benzinga
Lilly and NVIDIA: a $1bn leap for drug discovery - European Medical Journal
Can Novo Nordisk Unseat Eli Lilly as the Weight Loss Drug Leader in 2026? - Yahoo Finance
Eli Lilly (LLY) Targets Q2 2026 FDA Approval for Obesity Pill - GuruFocus
What to Expect From Eli Lilly’s Q4 2025 Earnings Report - Barchart.com
Eli Lilly CFO says obesity pill on track for FDA nod in Q2 - Seeking Alpha
Tokio Marine Asset Management Co. Ltd. Sells 2,739 Shares of Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Nividia Commit $1B Over 5 Years for AI-Driven Drug Discovery Lab - AI Insider
NVIDIA to Invest US$1 Billion in an AI Drug Laboratory with Eli Lilly - Eudaimonia and Co
New York State Teachers Retirement System Sells 4,205 Shares of Eli Lilly and Company $LLY - MarketBeat
Antidepressant Market Is Booming So Rapidly | Eli Lilly and Company, Pfizer Inc., GlaxoSmithKline PLC, AstraZeneca - openPR.com
Eli Lilly & Co (NYSE:LLY) Combines High Growth Momentum with a Strong Technical Setup - Chartmill
Eli Lilly Stock Rises on $1 Billion AI Bet With Nvidia - GuruFocus
Lilly Eli Co Azioni (LLY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.29%
1.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):